Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure
Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7–8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2006-10, Vol.98 (7), p.60-66 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | 7 |
| container_start_page | 60 |
| container_title | The American journal of cardiology |
| container_volume | 98 |
| creator | Hauptman, Paul J. Pressler, Susan J. Sackner-Bernstein, Jonathan Ordronneau, Paul Udelson, James E. |
| description | Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7–8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article. |
| doi_str_mv | 10.1016/j.amjcard.2006.08.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68927379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914906015268</els_id><sourcerecordid>1170944571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-b3823b9f18328131209a4525ca658f8d0e3bb4f231aed2412c8d15ae30c103423</originalsourceid><addsrcrecordid>eNqFkc1q3DAURkVpaaZpH6FFdNGd3SvJ9kjdlOAkTWAg6SRdC1m-TmX8M5HshHmfPmg1mYFCCWQlJJ3vSnyHkI8MUgas-Nqmpm-t8XXKAYoUZAqQvSILJpcqYYqJ12QBADxRLFNH5F0IbdwylhdvyRFbAhdcZAvyZ20mNw6mQ2qGmp5icHcDHRtantxcn62_0XLsN50zg90DP2fTuWm7I1auQXozzfX2CTLeDXf0KoLJqXFdPDT-AWvXjR0t10_h20f33O3lmrqBXseP4DAF-uim3_QCjZ_oeURnj-_Jm8Z0AT8c1mPy6_zstrxIVlc_LsuTVWKFgimphOSiUg2TgksmGAdlspzn1hS5bGQNKKoqa7hgBmueMW5lzXKDAiwDkXFxTL7s5278eD9jmHTvgsWuMwOOc9CFVHwpliqCn_8D23H2scWguQAhhZI7KN9D1o8heGz0xrve-K1moHcOdasPDvXOoQapo8OY-3QYPlc91v9SB2kR-L4HMHbx4NDrYGN1Ntbp0U66Ht0LT_wFcW6ucg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230383989</pqid></control><display><type>article</type><title>Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hauptman, Paul J. ; Pressler, Susan J. ; Sackner-Bernstein, Jonathan ; Ordronneau, Paul ; Udelson, James E.</creator><creatorcontrib>Hauptman, Paul J. ; Pressler, Susan J. ; Sackner-Bernstein, Jonathan ; Ordronneau, Paul ; Udelson, James E. ; CASPER Investigators</creatorcontrib><description>Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7–8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2006.08.004</identifier><identifier>PMID: 17023234</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adrenergic beta-Antagonists - administration & dosage ; Adrenergic beta-Antagonists - therapeutic use ; Beta blockers ; Carbazoles - administration & dosage ; Carbazoles - therapeutic use ; Chemistry, Pharmaceutical ; Clinical trials ; Comparative studies ; Compliance ; Delayed-Action Preparations - administration & dosage ; Delayed-Action Preparations - therapeutic use ; Drug dosages ; Heart failure ; Heart Failure - drug therapy ; Humans ; Patient Compliance ; Propanolamines - administration & dosage ; Propanolamines - therapeutic use ; Quality of Life ; Randomized Controlled Trials as Topic ; Research Design</subject><ispartof>The American journal of cardiology, 2006-10, Vol.98 (7), p.60-66</ispartof><rights>2006 Elsevier Inc.</rights><rights>Copyright Elsevier Sequoia S.A. Oct 2, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-b3823b9f18328131209a4525ca658f8d0e3bb4f231aed2412c8d15ae30c103423</citedby><cites>FETCH-LOGICAL-c390t-b3823b9f18328131209a4525ca658f8d0e3bb4f231aed2412c8d15ae30c103423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914906015268$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17023234$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hauptman, Paul J.</creatorcontrib><creatorcontrib>Pressler, Susan J.</creatorcontrib><creatorcontrib>Sackner-Bernstein, Jonathan</creatorcontrib><creatorcontrib>Ordronneau, Paul</creatorcontrib><creatorcontrib>Udelson, James E.</creatorcontrib><creatorcontrib>CASPER Investigators</creatorcontrib><title>Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7–8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.</description><subject>Adrenergic beta-Antagonists - administration & dosage</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Beta blockers</subject><subject>Carbazoles - administration & dosage</subject><subject>Carbazoles - therapeutic use</subject><subject>Chemistry, Pharmaceutical</subject><subject>Clinical trials</subject><subject>Comparative studies</subject><subject>Compliance</subject><subject>Delayed-Action Preparations - administration & dosage</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>Drug dosages</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Patient Compliance</subject><subject>Propanolamines - administration & dosage</subject><subject>Propanolamines - therapeutic use</subject><subject>Quality of Life</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research Design</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1q3DAURkVpaaZpH6FFdNGd3SvJ9kjdlOAkTWAg6SRdC1m-TmX8M5HshHmfPmg1mYFCCWQlJJ3vSnyHkI8MUgas-Nqmpm-t8XXKAYoUZAqQvSILJpcqYYqJ12QBADxRLFNH5F0IbdwylhdvyRFbAhdcZAvyZ20mNw6mQ2qGmp5icHcDHRtantxcn62_0XLsN50zg90DP2fTuWm7I1auQXozzfX2CTLeDXf0KoLJqXFdPDT-AWvXjR0t10_h20f33O3lmrqBXseP4DAF-uim3_QCjZ_oeURnj-_Jm8Z0AT8c1mPy6_zstrxIVlc_LsuTVWKFgimphOSiUg2TgksmGAdlspzn1hS5bGQNKKoqa7hgBmueMW5lzXKDAiwDkXFxTL7s5278eD9jmHTvgsWuMwOOc9CFVHwpliqCn_8D23H2scWguQAhhZI7KN9D1o8heGz0xrve-K1moHcOdasPDvXOoQapo8OY-3QYPlc91v9SB2kR-L4HMHbx4NDrYGN1Ntbp0U66Ht0LT_wFcW6ucg</recordid><startdate>20061002</startdate><enddate>20061002</enddate><creator>Hauptman, Paul J.</creator><creator>Pressler, Susan J.</creator><creator>Sackner-Bernstein, Jonathan</creator><creator>Ordronneau, Paul</creator><creator>Udelson, James E.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20061002</creationdate><title>Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure</title><author>Hauptman, Paul J. ; Pressler, Susan J. ; Sackner-Bernstein, Jonathan ; Ordronneau, Paul ; Udelson, James E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-b3823b9f18328131209a4525ca658f8d0e3bb4f231aed2412c8d15ae30c103423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adrenergic beta-Antagonists - administration & dosage</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Beta blockers</topic><topic>Carbazoles - administration & dosage</topic><topic>Carbazoles - therapeutic use</topic><topic>Chemistry, Pharmaceutical</topic><topic>Clinical trials</topic><topic>Comparative studies</topic><topic>Compliance</topic><topic>Delayed-Action Preparations - administration & dosage</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>Drug dosages</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Patient Compliance</topic><topic>Propanolamines - administration & dosage</topic><topic>Propanolamines - therapeutic use</topic><topic>Quality of Life</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research Design</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hauptman, Paul J.</creatorcontrib><creatorcontrib>Pressler, Susan J.</creatorcontrib><creatorcontrib>Sackner-Bernstein, Jonathan</creatorcontrib><creatorcontrib>Ordronneau, Paul</creatorcontrib><creatorcontrib>Udelson, James E.</creatorcontrib><creatorcontrib>CASPER Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hauptman, Paul J.</au><au>Pressler, Susan J.</au><au>Sackner-Bernstein, Jonathan</au><au>Ordronneau, Paul</au><au>Udelson, James E.</au><aucorp>CASPER Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2006-10-02</date><risdate>2006</risdate><volume>98</volume><issue>7</issue><spage>60</spage><epage>66</epage><pages>60-66</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Adherence to a complex medical regimen in patients with chronic heart failure is an important problem. In the Medicare population, patients with heart failure take an average of 7–8 distinct medications that require >11 separate doses on a daily basis. Nonadherence to these regimens accounts for a significant proportion of hospital admissions. Simplification of the medical regimen for patients with heart failure is likely to be associated with improved adherence and, in parallel, may lead to greater satisfaction and potentially improved outcomes. Therefore, the Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial has been designed to rigorously test the hypothesis that a once-daily formulation of carvedilol will result in better compliance and increased patient satisfaction relative to the twice-daily formulation. The background, methods, and statistical approaches used in this trial are reviewed in this article.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17023234</pmid><doi>10.1016/j.amjcard.2006.08.004</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2006-10, Vol.98 (7), p.60-66 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68927379 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adrenergic beta-Antagonists - administration & dosage Adrenergic beta-Antagonists - therapeutic use Beta blockers Carbazoles - administration & dosage Carbazoles - therapeutic use Chemistry, Pharmaceutical Clinical trials Comparative studies Compliance Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - therapeutic use Drug dosages Heart failure Heart Failure - drug therapy Humans Patient Compliance Propanolamines - administration & dosage Propanolamines - therapeutic use Quality of Life Randomized Controlled Trials as Topic Research Design |
| title | Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-22T00%3A34%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rationale%20and%20Design%20of%20CASPER:%20Compliance%20and%20Quality%20of%20Life%20Study%20Comparing%20Once-Daily%20Carvedilol%20CR%20and%20Twice-Daily%20Carvedilol%20IR%20in%20Patients%20with%20Heart%20Failure&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Hauptman,%20Paul%20J.&rft.aucorp=CASPER%20Investigators&rft.date=2006-10-02&rft.volume=98&rft.issue=7&rft.spage=60&rft.epage=66&rft.pages=60-66&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2006.08.004&rft_dat=%3Cproquest_cross%3E1170944571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230383989&rft_id=info:pmid/17023234&rft_els_id=S0002914906015268&rfr_iscdi=true |